Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Binge Disorders Pipeline Insight

DelveInsight’s, “Binge-Eating Disorder - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Binge-Eating Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Binge-Eating Disorder Understanding

Binge-Eating Disorder: Overview

Binge eating disorder (BED) is a mental illness characterised by regular episodes of binge eating. Binge eating involves eating an excessive amount of food, which may take place in a rapid space of time, or may be more of an extended grazing. These episodes can feel chaotic, uncontrollable and highly distressing. During a binge eating episode, a person may not be hungry, but may continue to eat past the point of feeling comfortably full. It is common for people to binge eat alone or in secret, and experience intense feelings of guilt, shame, disgust and low mood after a binge. A binge is different from overeating and is far more pervasive. It is the intense drive to overeat which is experienced again and again over time, accompanied by feelings of shame, guilt and feeling out of control.

 

"Binge-Eating Disorder - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Binge-Eating Disorder pipeline landscape is provided which includes the disease overview and Binge-Eating Disorder treatment guidelines. The assessment part of the report embraces, in depth Binge-Eating Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Binge-Eating Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Binge-Eating Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Binge-Eating Disorder.

Binge-Eating Disorder Emerging Drugs Chapters

This segment of the Binge-Eating Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Binge-Eating Disorder Emerging Drugs

 

SEP-225289: Sumitomo Dainippon Pharma

SEP-225289 is a dopamine and norepinephrine reuptake inhibitor (DNRI). SEP-225289 has an extended half-life (47-77 hours) that supports the potential for plasma concentrations yielding a continuous therapeutic effect over the 24-hour dosing interval.

 

ACT-539313: Idorsia Pharmaceuticals

ACT-539313 is an Orexin receptor type 1 antagonist being developed by Idorsia Pharmaceuticals. Currently, it is in Phase II stage of clinical trial evaluation to treat Binge-Eating Disorder.

Further product details are provided in the report……..

Binge-Eating Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Binge-Eating Disorder drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Binge-Eating Disorder

There are approx. 4+ key companies which are developing the therapies for Binge-Eating Disorder. The companies which have their Binge-Eating Disorder drug candidates in the most advanced stage, i.e. phase II include, Idorsia Pharmaceuticals.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Binge-Eating Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Binge-Eating Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Binge-Eating Disorder therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Binge-Eating Disorder drugs.

Binge-Eating Disorder Report Insights

  • Binge-Eating Disorder Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Binge-Eating Disorder Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Binge-Eating Disorder drugs?
  • How many Binge-Eating Disorder drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Binge-Eating Disorder?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Binge-Eating Disorder therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Binge-Eating Disorder and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Binge-Eating Disorder: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Binge-Eating Disorder – DelveInsight’s Analytical Perspective

Late Stage Products (Preregistration)

  • Comparative Analysis

SEP-225289: Sumitomo Dainippon Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

ACT-539313: Idorsia Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

BMB-101: Bright Minds Biosciences

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Binge-Eating Disorder Key Companies

Binge-Eating Disorder Key Products

Binge-Eating Disorder- Unmet Needs

Binge-Eating Disorder- Market Drivers and Barriers

Binge-Eating Disorder- Future Perspectives and Conclusion

Binge-Eating Disorder Analyst Views

Binge-Eating Disorder Key Companies

Appendix

List of Table

Table 1: Total Products for Binge-Eating Disorder

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Binge-Eating Disorder

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Sumitomo Dainippon Pharma
• Idorsia Pharmaceuticals
• Takeda
• Bright Minds Biosciences
• Praxis Bioresearch

 

Forward to Friend

Need A Quote